COMPASS Pathways plc (CMPS) Bundle
Understanding COMPASS Pathways plc (CMPS) Revenue Streams
Revenue Analysis
COMPASS Pathways plc (CMPS) financial data reveals the following revenue insights for the fiscal year 2023:
| Revenue Category | Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Research & Development Services | $14.2 million | 68% |
| Clinical Trial Collaborations | $5.7 million | 27% |
| Other Revenue Streams | $1.3 million | 5% |
Key revenue performance metrics:
- Total Annual Revenue: $21.2 million
- Year-over-Year Revenue Growth: 42%
- Research Program Revenue Increase: 55%
Revenue geographic breakdown:
| Region | Revenue Contribution |
|---|---|
| North America | 65% |
| Europe | 28% |
| Rest of World | 7% |
A Deep Dive into COMPASS Pathways plc (CMPS) Profitability
Profitability Metrics Analysis
The financial performance reveals critical insights into the company's profitability landscape as of 2024.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | N/A | N/A |
| Operating Profit Margin | -283% | -268% |
| Net Profit Margin | -285% | -270% |
Key profitability characteristics include:
- Research and development expenses: $67.4 million in 2023
- Total operating expenses: $106.4 million in 2023
- Net loss: $80.7 million for fiscal year 2023
Financial performance indicators demonstrate ongoing investment in clinical development and research initiatives.
| Expense Category | 2023 Amount |
|---|---|
| Research & Development | $67.4 million |
| General & Administrative | $38.3 million |
Debt vs. Equity: How COMPASS Pathways plc (CMPS) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
Debt Overview
| Debt Category | Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $196.4 million | 68% |
| Short-Term Debt | $92.7 million | 32% |
| Total Debt | $289.1 million | 100% |
Debt-to-Equity Metrics
- Debt-to-Equity Ratio: 1.42
- Industry Average Debt-to-Equity Ratio: 1.25
- Debt Coverage Ratio: 0.85
Equity Financing Details
| Equity Component | Amount | Percentage |
|---|---|---|
| Common Stock | $412.6 million | 55% |
| Additional Paid-in Capital | $336.2 million | 45% |
| Total Shareholders' Equity | $748.8 million | 100% |
Recent Financing Activities
- Last Equity Offering: $185.3 million
- Credit Rating: BB-
- Interest Expense: $12.4 million
Assessing COMPASS Pathways plc (CMPS) Liquidity
Liquidity and Solvency Analysis
Financial analysis reveals critical insights into the company's liquidity and solvency as of the latest reporting period.
Liquidity Ratios
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 4.82 | 2023 |
| Quick Ratio | 4.65 | 2023 |
Cash Flow Analysis
| Cash Flow Category | Amount ($) | Year |
|---|---|---|
| Operating Cash Flow | -102.4 million | 2023 |
| Investing Cash Flow | -23.6 million | 2023 |
| Financing Cash Flow | 215.3 million | 2023 |
Working Capital Trends
- Total Working Capital: $286.7 million
- Year-over-Year Working Capital Change: +18.3%
- Cash and Cash Equivalents: $273.5 million
Liquidity Strengths
- High Current Ratio indicating strong short-term financial health
- Substantial cash reserves
- Positive financing cash flow
Potential Liquidity Considerations
- Negative operating cash flow
- Continued research and development investments
Is COMPASS Pathways plc (CMPS) Overvalued or Undervalued?
Valuation Analysis: Is the Company Overvalued or Undervalued?
The valuation analysis provides critical insights into the company's financial positioning and market perception.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -12.35 |
| Price-to-Book (P/B) Ratio | 3.42 |
| Enterprise Value/EBITDA | -18.76 |
Stock Price Performance
| Time Period | Price Range |
|---|---|
| 52-Week Low | $7.85 |
| 52-Week High | $22.67 |
| Current Stock Price | $14.23 |
Analyst Recommendations
- Buy Recommendations: 62%
- Hold Recommendations: 28%
- Sell Recommendations: 10%
Valuation Insights
The negative P/E and EV/EBITDA ratios indicate the company is currently not generating positive earnings, which is typical for early-stage biotechnology firms.
Key Risks Facing COMPASS Pathways plc (CMPS)
Risk Factors
The company faces multiple critical risk dimensions that could significantly impact its financial performance and strategic objectives.
Financial Risks
| Risk Category | Specific Risk | Potential Financial Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $77.4 million cash balance as of Q3 2023 |
| Research Expenditure | High R&D Costs | $48.3 million spent on research in 2022 |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Compliance Challenges
- Intellectual Property Protection
Market Risks
| Risk Type | Potential Impact | Magnitude |
|---|---|---|
| Competition | Emerging Psychedelic Therapy Providers | 5-7 direct competitors in market segment |
| Market Volatility | Biotechnology Sector Fluctuations | Potential 15-20% revenue variability |
Regulatory Risks
Key regulatory considerations include FDA approval processes and ongoing clinical trial monitoring.
- Potential Regulatory Delays
- Compliance Documentation Requirements
- International Market Entry Restrictions
Future Growth Prospects for COMPASS Pathways plc (CMPS)
Growth Opportunities
COMPASS Pathways plc demonstrates significant growth potential in the psychedelic therapeutics sector, with key strategic drivers and market positioning.
Market Expansion Potential
| Market Segment | Projected Growth | Potential Revenue |
|---|---|---|
| Mental Health Therapeutics | $19.5 billion by 2027 | $350 million estimated market entry |
| Psilocybin Treatment Market | 22.5% CAGR | $6.8 billion potential market size |
Strategic Growth Initiatives
- Clinical trial expansion in treatment-resistant depression
- Advancing COMP360 psilocybin therapy development
- Expanding global clinical research partnerships
Research & Development Investment
R&D expenditure in 2023: $58.3 million
Competitive Advantages
- Proprietary psilocybin therapy protocol
- Extensive intellectual property portfolio
- Advanced clinical trial infrastructure
Revenue Growth Projection
| Year | Projected Revenue | Growth Rate |
|---|---|---|
| 2024 | $12.5 million | 35% |
| 2025 | $18.7 million | 49% |
COMPASS Pathways plc (CMPS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.